Home > Annual Financials > VENUS REMEDIES

VENUS REMEDIES Financial Statement Analysis
[BOM: 526953|NSE : VENUSREM]

The Revenues of VENUS REMEDIES have increased by 7.72% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 59.08 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]

ConsolidatedMar2025
Mar2024
Mar2023
Mar2022
Mar2021
Revenues ₹648 Cr₹601 Cr₹556 Cr₹600 Cr₹548 Cr
Expenses ₹584 Cr₹542 Cr₹495 Cr₹538 Cr₹494 Cr
Operating Profit (Excl OI) ₹64 Cr₹60 Cr₹60 Cr₹62 Cr₹54 Cr
Other Income ₹21 Cr₹12 Cr₹10 Cr₹8.31 Cr₹20 Cr
Interest ₹0.07 Cr₹0.09 Cr₹0.12 Cr₹0.48 Cr₹13 Cr
Depreciation ₹23 Cr₹26 Cr₹32 Cr₹34 Cr₹35 Cr
Profit Before Tax ₹72 Cr₹45 Cr₹38 Cr₹36 Cr₹49 Cr
Profit After Tax ₹45 Cr₹28 Cr₹27 Cr₹41 Cr₹62 Cr
Consolidated Net Profit ₹45 Cr₹28 Cr₹27 Cr₹41 Cr₹62 Cr
Earnings Per Share (Rs)₹33.90₹21.31₹19.87₹30.47₹50.04
PAT Margin (%)6.994.744.786.7911.27
ROE(%)8.646.015.909.8517.40
ROCE(%)13.178.677.727.8912.37
Total Debt/Equity(x)0.000.080.090.100.13

Key Financials

Market Cap : ₹ 632.5 Cr
Revenue (TTM) : ₹ 671.2 Cr
Net Profit(TTM) : ₹ 53.7 Cr
EPS (TTM) : ₹ 40.1
P/E (TTM) : 11.8

Industry Peers & Returns1W1M1Y
VENUS REMEDIES -3.5% -10% 22.3%
SUN PHARMACEUTICAL INDUSTRIES 3.5% -3.4% -5.8%
DIVIS LABORATORIES 3.7% -10.2% 25.6%
CIPLA 5.3% 6.1% -1.3%
TORRENT PHARMACEUTICALS 1.4% 4.6% 7.6%
DR REDDYS LABORATORIES 3.9% 0% -9.9%
MANKIND PHARMA 0.3% -5.8% 13.5%
ZYDUS LIFESCIENCES 5.7% 2.1% -15.9%
LUPIN 2.3% 1.6% -5.3%


VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

7.72 %

5 Yr CAGR

4.27 %

Years Revenues % Change
Mar2025 ₹648 Cr
7.72
Mar2024 ₹601 Cr
8.27
Mar2023 ₹556 Cr
-7.44
Mar2022 ₹600 Cr
9.50
Mar2021 ₹548 Cr -


VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

6.59 %

5 Yr CAGR

4.25 %

Years Operating Profit % Change
Mar2025 ₹64 Cr
6.59
Mar2024 ₹60 Cr
-0.71
Mar2023 ₹60 Cr
-3.36
Mar2022 ₹62 Cr
15.50
Mar2021 ₹54 Cr -

Operating Margins
Y-o-Y

-1.01 %

5 Yr CAGR

0.00 %

Years Operating Margin% % Change
Mar2025 9.81%
-1.01
Mar2024 9.91%
-8.33
Mar2023 10.81%
4.44
Mar2022 10.35%
5.50
Mar2021 9.81% -

VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

59.05 %

5 Yr CAGR

-7.45 %

Years Profit After Tax % Change
Mar2025 ₹45 Cr
59.05
Mar2024 ₹28 Cr
7.25
Mar2023 ₹27 Cr
-34.77
Mar2022 ₹41 Cr
-34.07
Mar2021 ₹62 Cr -

PAT Margins
Y-o-Y

47.47 %

5 Yr CAGR

-11.26 %

Years PAT Margin(%) % Change
Mar2025 6.99 %
47.47
Mar2024 4.74 %
-0.84
Mar2023 4.78 %
-29.60
Mar2022 6.79 %
-39.75
Mar2021 11.27 % -

VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

59.08 %

5 Yr CAGR

-9.28 %

Years EPS % Change
Mar2025 ₹34
59.08
Mar2024 ₹21
7.25
Mar2023 ₹20
-34.79
Mar2022 ₹30
-39.11
Mar2021 ₹50 -

VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

51.90 %

5 Yr CAGR

1.58 %

Years ROCE % Change
Mar2025 13.17%
51.90
Mar2024 8.67%
12.31
Mar2023 7.72%
-2.15
Mar2022 7.89%
-36.22
Mar2021 12.37% -

VENUS REMEDIES Share Price vs Sensex

Current Share Price : ₹472.1
Current MarketCap: ₹ 632.5 Cr
Updated EOD on :Aug 14,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
VENUS REMEDIES

-3.5%

-10%

22.3%

SENSEX

-0%

-2.4%

1.2%

VENUS REMEDIES related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about VENUS REMEDIES Financials


How the annual revenues of VENUS REMEDIES have changed ?

The Revenues of VENUS REMEDIES have increased by 7.72% YoY .

How the Earnings per Share (EPS) of VENUS REMEDIES have changed?

The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 59.08 % YoY .